Pomalidomide

FDA Approved: * October 30, 2020
Pharm Company: * BRECKENRIDGE
Category: Cancer

Pomalidomide (INN; marketed as Pomalyst in the US[3] and Imnovid in the European Union and Russia) is a derivative of thalidomide marketed by Celgene. It is anti-angiogenic and also acts as an immunomodulator.[medical citation needed] Pomalidomide was approved in February 2013, by the US Food and Drug Administration (FDA) as a treatment for relapsed and refractory multiple myeloma.[6] It has been approved for use in people who have received at ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Pomalidomide 3 mg Oral Capsule
NDC: 0480-2601
Labeler:
Teva Pharmaceuticals, Inc.
Pomalidomide 1 mg Oral Capsule
NDC: 0480-4018
Labeler:
Teva Pharmaceuticals, Inc.
Pomalidomide 2 mg Oral Capsule
NDC: 0480-4022
Labeler:
Teva Pharmaceuticals, Inc.
Pomalidomide 4 mg Oral Capsule
NDC: 0480-4035
Labeler:
Teva Pharmaceuticals, Inc.
Pomalidomide 1 mg Oral Capsule
NDC: 31722-770
Labeler:
Camber Pharmaceuticals, Inc.
Pomalidomide 2 mg Oral Capsule
NDC: 31722-771
Labeler:
Camber Pharmaceuticals, Inc.
Pomalidomide 3 mg Oral Capsule
NDC: 31722-772
Labeler:
Camber Pharmaceuticals, Inc.
Pomalidomide 4 mg Oral Capsule
NDC: 31722-773
Labeler:
Camber Pharmaceuticals, Inc.
Pomalidomide 1 mg Oral Capsule
NDC: 51991-342
Labeler:
Breckenridge Pharmaceutical, Inc.
Pomalidomide 2 mg Oral Capsule
NDC: 51991-343
Labeler:
Breckenridge Pharmaceutical, Inc.
More Results

Related Brands

Drugs with the same active ingredients